What is Cellomics Technology?
Operating at the intersection of molecular biology and biotechnology, Cellomics Technology provides essential infrastructure for the global research community. The company specializes in the development of high-precision lentiviral vectors, specialized cell culture reagents, and bespoke gene targeting services. By focusing on the complexities of somatic and stem cell genetic engineering, the firm has established itself as a critical partner for laboratories engaged in stable cell line generation. Their product suite is engineered to accelerate the pace of discovery in genetic medicine, providing researchers with the reliable, high-quality tools necessary for complex genomic manipulation.
How much funding has Cellomics Technology raised?
Cellomics Technology has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2024): $150K with participation from Bank of America
Key Investors in Cellomics Technology
Bank of America
A global financial institution providing comprehensive banking and investment services to support corporate growth and capital structure optimization.
What's next for Cellomics Technology?
With this recent strategic investment, Cellomics Technology is well-positioned to scale its operational capacity and expand its footprint in the competitive gene editing landscape. The infusion of capital will likely be directed toward enhancing manufacturing capabilities for viral vectors and broadening the scope of their custom service offerings. As the demand for sophisticated gene engineering tools continues to rise, the company is expected to leverage this financial backing to deepen its R&D initiatives, potentially exploring new frontiers in therapeutic delivery mechanisms. This late-stage funding serves as a catalyst for long-term sustainability, enabling the firm to maintain its trajectory as a key supplier in the life sciences sector while navigating the complexities of a rapidly evolving biotechnology market.
See full Cellomics Technology company page
